WebDoctor Encyclopedia

Article

Immune Checkpoint Inhibitors (PD-1, PD-L1 and CTLA-4)

What are immune checkpoint inhibitors?

Immune checkpoint inhibitors are a type of immunotherapy. They are medicines that release the brakes on the immune system, so that it can recognise and attack cancer cells more effectively. They are given as a drip into a vein, usually every few weeks.

The immune system has built-in “checkpoints”, which are signals that stop immune cells from attacking the body’s own tissues. Many cancers exploit these checkpoints to hide from the immune system. Checkpoint inhibitors block these signals and let T cells (white blood cells that fight infection and cancer) do their job.

These drugs have changed the outlook for several cancers that were once very hard to treat, including advanced melanoma, lung cancer and kidney cancer. Some people treated with them remain well for many years. However, they do not work for everyone, and they can cause unusual side effects when the immune system attacks healthy organs.

The main types

Target How it works Examples of drugs
PD-1 Blocks a brake receptor on T cells Nivolumab, pembrolizumab, cemiplimab, dostarlimab
PD-L1 Blocks the partner molecule that tumours use to switch off T cells Atezolizumab, durvalumab, avelumab
CTLA-4 Blocks an early brake that limits T cell activation in lymph nodes Ipilimumab, tremelimumab
LAG-3 Blocks another brake on T cells, used with a PD-1 drug Relatlimab

A brief history

Scientists discovered CTLA-4 and PD-1 in the 1980s and 1990s while studying how the immune system avoids attacking healthy tissue. James Allison and Tasuku Honjo showed that blocking these brakes could make tumours shrink in laboratory models, work that earned them the Nobel Prize in 2018. Ipilimumab became the first approved checkpoint inhibitor in 2011, followed by the first PD-1 drugs in 2014.

1. Key facts at a glance

Feature Details
Type of treatment Immunotherapy (monoclonal antibodies)
Main uses Melanoma, lung, kidney, bladder, head and neck cancers, and many more
How it is given Drip into a vein over 30-60 minutes; some drugs now under the skin
Frequency Every 2, 3, 4 or 6 weeks, depending on the drug
Course length Often up to 1-2 years, or less after surgery
Used with Alone, in pairs, or with chemotherapy or targeted therapy
Common side effects Tiredness, rash, itching, diarrhoea, thyroid problems
Serious side effects Inflammation of the bowel, lungs, liver, hormone glands, heart or other organs

2. How it works

The immune brakes

Checkpoint Normal job What happens in cancer What the drug does
CTLA-4 Limits T cell activation at an early stage, mainly in lymph nodes Keeps the immune response weak from the start Lets more T cells become active against the cancer
PD-1 / PD-L1 Switches off T cells in tissues to prevent damage Tumours display PD-L1 to turn off T cells that reach them Lets T cells inside the tumour keep attacking

Because the drugs act on the immune system rather than directly on the cancer, responses can take longer to appear than with chemotherapy. Occasionally, tumours look bigger on early scans because immune cells move in, before they shrink. This is called pseudoprogression, though it is uncommon.

Markers that help predict response

Marker Meaning
PD-L1 level Higher levels on tumour cells often predict a better chance of response in lung cancer and some other cancers
Mismatch repair deficiency (dMMR) or MSI-high Tumours with many mutations are more visible to the immune system
Tumour mutational burden A higher number of mutations may predict benefit

3. Who it is for

Conditions treated

Condition Typical role
Melanoma Advanced disease and after surgery for higher-risk melanoma
Non-small cell lung cancer Advanced disease, with or without chemotherapy; also around surgery and after chemoradiotherapy
Small cell lung cancer Added to chemotherapy for extensive stage
Clear cell renal cell carcinoma Advanced disease, often combined with another drug
Urothelial carcinoma of the bladder Advanced disease and after surgery in some people
Merkel cell carcinoma Advanced disease
Cutaneous squamous cell carcinoma Advanced disease not suitable for surgery or radiotherapy
Hodgkin lymphoma Relapsed disease, and increasingly in first-line treatment
Hepatocellular carcinoma Advanced disease, often with another drug
Triple-negative breast cancer With chemotherapy before and after surgery, and in advanced disease
Colorectal adenocarcinoma Tumours with mismatch repair deficiency
Endometrial cancer With chemotherapy, especially for mismatch repair-deficient tumours
Malignant pleural mesothelioma Combination immunotherapy for advanced disease

Who may need extra caution

Situation Reason
Active autoimmune disease Such as severe Crohn’s disease or lupus, which may flare
Organ transplant Risk of rejection
High-dose steroids May reduce the effect of treatment
Very poor general health Benefit is less likely

4. Before treatment

Step Why it is done
Tumour testing PD-L1, mismatch repair or other markers, depending on the cancer
Blood tests Baseline thyroid, liver, kidney, blood sugar and cortisol levels
Scans To measure the cancer before treatment
Medical history Autoimmune conditions and infections such as hepatitis
Patient alert card You carry it so any doctor knows you are on immunotherapy

5. What to expect: step by step

Step What happens
1. Blood tests Usually a day or two before each treatment
2. Review A doctor, nurse or pharmacist checks for side effects
3. Drip A cannula is placed and the drug is given over about 30-60 minutes
4. Short observation Especially after the first doses
5. Home Most people go home the same day
6. Repeat Every 2-6 weeks depending on the drug
7. Scans Usually every 2-3 months

Combination immunotherapy

When ipilimumab and nivolumab are given together, the first four doses are given every three weeks, followed by nivolumab alone. This combination is more effective in some cancers but causes more side effects.

6. Side effects and risks

Side effects of checkpoint inhibitors are called immune-related adverse events. They happen when activated immune cells attack healthy tissues. They can appear at any time, including months after treatment has stopped. A review of these effects notes that their exact cause is still not fully understood (Yin et al., 2023).

Organ Possible problem Warning signs
Skin Rash, itching, vitiligo Itchy rash, blisters, loss of skin colour
Bowel Colitis Diarrhoea, blood in stool, tummy pain
Liver Hepatitis Yellow skin, dark urine; often found on blood tests
Lungs Pneumonitis New cough or breathlessness
Thyroid Overactive or underactive thyroid Tiredness, weight change, feeling hot or cold
Pituitary gland Hypophysitis Headache, tiredness, dizziness
Adrenal glands Adrenal insufficiency Weakness, low blood pressure, vomiting
Pancreas Type 1 diabetes Thirst, passing more urine, weight loss
Joints and muscles Arthritis, myositis Pain, stiffness, weakness
Heart Myocarditis (rare but serious) Chest pain, palpitations, breathlessness
Nerves Neuropathy, myasthenia-like illness (rare) Weakness, drooping eyelids, double vision

How side effects are treated

Severity Usual approach
Mild Continue treatment with symptom relief and monitoring
Moderate Pause treatment; start steroids
Severe Stop treatment; high-dose steroids, sometimes in hospital; other immune-suppressing drugs if needed
Hormone deficiencies Lifelong hormone replacement, such as thyroxine or hydrocortisone

A review of chronic side effects found that some problems, especially hormone deficiencies, arthritis and dry mouth, can persist for many months after treatment ends (Fletcher and Johnson, 2024).

When to call for help

Side effects of immunotherapy can look like ordinary illnesses, such as a stomach bug or a chest infection. Doctors who do not know you are on immunotherapy may not recognise them. Call your cancer team’s helpline straight away if you have diarrhoea several times a day, new breathlessness or cough, chest pain, severe headache, yellowing of the skin or sudden weakness. Show your alert card at any emergency department.

7. Results and outlook

Study Main finding
CheckMate 067, advanced melanoma (945 people) Five-year survival was 52% with nivolumab plus ipilimumab, 44% with nivolumab alone and 26% with ipilimumab alone (Larkin et al., 2019)
KEYNOTE-024, lung cancer with high PD-L1 (305 people) Five-year survival was about 32% with pembrolizumab versus about 16% with chemotherapy (Reck et al., 2021)

These figures show a key feature of checkpoint inhibitors: a proportion of people have long-lasting responses, sometimes continuing after treatment stops. Before these drugs, long-term survival with advanced melanoma was rare.

Who responds?

Not everyone benefits. Response rates vary widely between cancers and between individuals, from under one in five to over half. Researchers are studying markers, gut bacteria and new combinations to help more people respond.

Quality of life

Many people find that checkpoint inhibitors are easier to live with than chemotherapy, with less sickness and no hair loss. In CheckMate 067, people treated with regimens containing nivolumab did not show a lasting decline in quality of life during or after treatment (Larkin et al., 2019). Even so, a minority develop severe side effects, so close monitoring remains essential.

Treatment before or after surgery

Checkpoint inhibitors are increasingly given before surgery (neoadjuvant) or after surgery (adjuvant) to lower the risk of cancer returning. This is now standard for some people with melanoma, lung, kidney, bladder and triple-negative breast cancers. Treatment in this setting is usually limited to about a year.

8. Recovery and aftercare

During and after treatment

Tip Why
Carry your alert card Any doctor treating you needs to know about immunotherapy
Report new symptoms early Most side effects are easier to treat when caught early
Do not stop steroids suddenly Steroids must be reduced gradually
Keep up blood tests Many side effects show up first in blood results
Get vaccinations as advised Inactivated vaccines such as flu are usually recommended

Follow-up after finishing

Period What to expect
First year Scans and blood tests every few months
Years 2-5 Less frequent scans
Long term Ongoing hormone replacement if needed

Fertility and pregnancy

Checkpoint inhibitors can cross the placenta and may harm a developing baby. Use effective contraception during treatment and for several months afterwards, as advised. Effects on long-term fertility are not yet well understood, so discuss egg or sperm storage before starting if you may want children in the future.

9. Alternatives

Alternative When it is considered
Targeted therapy Cancers with driver mutations, such as BRAF, EGFR or ALK
Chemotherapy Alone or combined with immunotherapy
Surgery or radiotherapy Localised disease
CAR-T or other cell therapies Some blood cancers
Clinical trials New immunotherapy combinations
Best supportive care When treatment is unlikely to help

Looking after yourself

Gentle exercise, a balanced diet and good sleep can help with tiredness. Keep a note of any new symptoms, even small ones, and bring it to each appointment. Let your GP and dentist know that you are on immunotherapy.

10. Frequently asked questions

Question Answer
Will I lose my hair? Hair loss is uncommon with checkpoint inhibitors alone
How quickly does it work? Often over weeks to months
Can side effects start after treatment stops? Yes, sometimes months later
Do steroids stop immunotherapy working? Steroids for side effects do not appear to cancel the benefit in most people
Can I work during treatment? Many people do
How long will I have treatment? Often up to two years for advanced disease, or one year after surgery
What if I have an autoimmune disease? It may still be possible with close monitoring; discuss with your team

11. Questions to ask your care team

  • Which checkpoint inhibitor do you recommend, and why?
  • Will I have one drug or a combination?
  • What side effects should I report immediately, and to whom?
  • How long will treatment last?
  • How will we know if it is working?
  • What happens if I need steroids?
  • Are there clinical trials I could join?

Resources

  1. Fletcher, K. and Johnson, D.B. (2024) ‘Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update’, Journal for ImmunoTherapy of Cancer, 12(7), e008591.
  2. Larkin, J. et al. (2019) ‘Five-year survival with combined nivolumab and ipilimumab in advanced melanoma’, New England Journal of Medicine, 381(16), pp. 1535-1546.
  3. Reck, M. et al. (2021) ‘Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or more’, Journal of Clinical Oncology, 39(21), pp. 2339-2349.
  4. Yin, Q. et al. (2023) ‘Immune-related adverse events of immune checkpoint inhibitors: a review’, Frontiers in Immunology, 14, 1167975.
  5. National Cancer Institute (2026) Immune Checkpoint Inhibitors. Available at: https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors (Accessed: October 2026).

Prepared by the editorial team, October 2026.